Top Headlines

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

Global Industry News

Hot Topics

Spotlight

Follow us

Products

View more

Featured Suppliers

All suppliers